Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
384 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)
This report on Circulating Tumor Cells (CTC) Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC industry, covering more than 150 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific with 53 exclusive graphically represented exhibits.
Table of Content I. SCOPE AND METHODOLOGY 1 2. REPORT SYNOPSIS 3 Circulating Tumor Cells (CTC) Technologies – Introduction 3 Circulating Tumor Cells (CTC) Technologies – Timeline 6 Biomarkers 7 CTC as a Biomarker 8 Process of Metastatic Development, CTCs and Cancer Stem Cells 8 CTCs in Blood and DTCs in Bone Marrow 9 Circulating Tumor Cells and Their Clinical Significance 9 Detection of CTCs and its Significance 10 Epithelial Mesenchymal Transition 11 Technologies for Isolation and Characterization of CTCs 11 Cell Free Nucleic Acids based CTC detection 11 CTC Detection on Physical Properties Basis 12 Antibody Capture Technology 12 Miscellaneous CTC Detection Strategies 13 CTC and Prostate Cancer 14 CTC in Breast Cancer 14 CTCs in Ovarian Cancer 14 CTC Diagnosis & Prognosis 14 CTCs as Therapy Response Marker 15 Segmentation 15 Exhibit 1. Segmentation of Global CTC Technologies Market by Cancer Type and by Function 15 CTC Technologies - Global Market Analysis 16 Exhibit 2. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Billion 16 Exhibit 3. List of Major Global Companies – CTC Technologies 17 3. MARKET DYNAMICS 19 CTCs - FOREWORD 19 CTCs – Impact 21 Global CTC Technologies Market 22 Exhibit 4. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World 22 Exhibit 5. CTC Technologies – Global Market Shares (2010 & 2015) for North America, Europe, Asia-Pacific and Rest of World 23 Exhibit 6. Circulating Tumor Cells - Global Market Analysis (2010 - 2020) for Per Test Cost, Number of Tests and Cancer Incidence 24 Cancer – The Global Scene 24 Exhibit 7. List of Product/Technologies for CTC Analysis 25 North American CTC Technologies Market 27 Exhibit 8. CTC Technologies – North American Market Estimations and Predictions (2010-2020) in US$ Million 27 United States Market Analysis 28 Exhibit 9. CTC Technologies – United States Market Estimations and Predictions (2010-2020) in US$ Million 28 Cancer Statistics 29 Exhibit 10. United States Cancer Incidence – Estimated Cases and Deaths in 2012 29 Cancer Care Cost 30 Exhibit 11. Cancer Care – National Cost (2010) by Cancer Site in US$ Billion 30 Exhibit 12. Cancer Care - Annual Costs (2010) in US$ 31 Exhibit 13. CTC Technologies - Major Organizations in the North America 32 European CTC Technologies Market 33 Exhibit 14. CTC Technologies – European Market Estimations and Predictions (2010-2020) in US$ Million 33 Market Snapshots 34 Cancer Statistics 35 Exhibit 15. European Union Cancer Incidence – Reported Cases and Deaths in 2008 35 United Kingdom 36 Exhibit 16. CTC Technologies - Major Organizations in the United Kingdom 36 Germany 37 Exhibit 17. CTC Technologies - Major Organizations in Germany 37 France 38 Exhibit 18. CTC Technologies - Major Organizations in France 38 Switzerland 39 Exhibit 19. CTC Technologies - Major Organizations in Switzerland 39 Exhibit 20. CTC Technologies - Major Organizations in Rest of Europe 39 Asia-Pacific CTC Technologies Market 40 Exhibit 21. CTC Technologies – Asia-Pacific Market Estimations and Predictions (2010-2020) in US$ Million 40 Japan 41 Exhibit 22. CTC Technologies - Major Organizations in Japan 41 India 42 Exhibit 23. Cancer Incidence in India - Reported Cases and Deaths in 2008 42 Exhibit 24. CTC Technologies - Major Organizations in India 42 Rest of Asia-Pacific 43 Exhibit 25. Cancer Incidence in China - Reported Cases and Deaths in 2008 43 Exhibit 26. CTC Technologies - Major Organizations in Rest of Asia-Pacific 43 Rest of World CTC Technologies Market 44 Exhibit 27. CTC Technologies – Rest of World Market Estimations and Predictions (2010-2020) in US$ Million 44 Israel 45 Exhibit 28. CTC Technologies - Major Organizations in Israel 45 CTC Technologies Providers – Competitor Profiles 46 Abnova Corporation (Taiwan) 46 AdnaGen AG (Germany) 47 Advanced Cell Diagnostics, Inc. (USA) 49 Affymetrix, Inc. (USA) 50 Amnis Corporation (USA) 51 ANGLE plc (UK) 52 ApoCell, Inc. (USA) 52 Applied Precision, Inc. (USA) 54 Applied Spectral Imaging, Inc. (USA) 55 Atossa Genetics, Inc. (USA) 56 AVIVA BioSciences Corporation (USA) 56 BioCEP Ltd. (Israel) 57 Biocept, Inc. (USA) 58 BioCytics, Inc. (USA) 59 BioFluidica, Inc. (USA) 60 BioView Ltd. (Israel) 62 Cancer Research UK Manchester Institute (UK) 63 Canopus Bioscience Ltd. (Canada) 64 CellTraffix, Inc. (USA) 66 Clearbridge BioMedics (Singapore) 67 Creatv MicroTech, Inc. (USA) 69 Cynvenio Biosystems, Inc. (USA) 70 CytoTrack ApS (Denmark) 71 DeNovo Sciences (USA) 73 Technology 75 DTU Fotonik (Denmark) 75 eOptra LLC (USA) 76 Epic Sciences, Inc. (USA) 77 F. Hoffmann-La Roche Ltd. (Switzerland) 77 Fluidigm Corporation (USA) 79 Fluxion Biosciences, Inc. (USA) 80 Genoptix Inc. (USA) 81 GILUPI GmbH (Germany) 82 Greiner Bio-One GmbH (Germany) 83 Ikonisys, Inc. (USA) 83 IMEC (Belgium) 84 IV Diagnostics, Inc. (USA) 85 Janssen Diagnostics BVBA (Belgium) 86 Janssen Diagnostics, LLC (USA) 86 Laboratory Dr. Pachmann (Germany) 89 Life Technologies (USA) 90 Liquid Biopsy AB (Sweden) 94 Miltenyi Biotec, Inc. (USA) 94 OncoGenex Pharmaceuticals, Inc. (USA) 95 OncoVista Innovative Therapies, Inc. (USA) 97 Progenics Pharmaceuticals, Inc. (USA) 98 R.G.C.C. International GmbH (Switzerland) 99 RareCells SAS (France) 100 RareCyte, Inc. (USA) 101 ScreenCell (France) 102 Silicon Biosystems SpA (Italy) 103 SIMFO GmbH (Germany) 104 STEMCELL Technologies, Inc. (Canada) 105 TeloVISION, LLC (USA) 106 Transgenomic, Inc. (USA) 106 Vitatex, Inc. (USA) 108 Significant Market Developments 112 Fluxion Biosciences Launches IsoFlux™ NGS Assay Kits for Circulating Biomarker Detection 112 Biocept Introduces Clinical Research Services for Biomarker Detection in Circulating Tumor DNA 112 DeNovo Sciences Introduces JETTA100, Its First Commercial Instrument and Consumables 112 Thermo Fisher Acquires Life Technologies 113 Fluxion Biosciences Includes Clinical Sample Procurement to Expand IsoFlux Discovery Services 113 Epic Sciences and LabCorp Collaborate to Expedite European Clinical Sample Processing for CTC Technology 113 National Cancer Centre Singapore Partners with Clearbridge BioMedics Establishes "Singapore CTC CoRE" 114 Abnova Launches CytoQuest™ CR 114 Vitatex Licenses Proprietary CAM CTC Technology to Noble 115 ApoCell Ventures into Europe, Pools Resources with the Fraunhofer Institute for Cell Therapy and Immunology 115 ApoCell Receives Phase II Contract by Small Business Innovation Research Program 116 Advanced Cell Diagnostics Enters into Collaboration with Kindstar Global to Launch Cancer Diagnostic Tests in China 116 IMEC and SPTS Collaborate on Advanced Nanotechnology Applications in BioMEM 117 Sysmex Inostics and Bayer HealthCare Enter into Collaboration for the Development of Blood-based Companion Diagnostic Tests for Targeted Tumor Therapies 117 Sysmex Acquires Two Germany based Companies to Expand its Technology Platform Targeting Personalized Medicine and Enter New Business Fields 117 Nektar Introduces Target Specific Biomarkers for the Development of Etirinotecan Pegol 118 Clearbridge BioMedics Launches ClearCell® FX 119 GILUPI GmbH Expands Business in the Asian Markets & Attains CE-Certification for CellCollector 119 IVDIAGNOSTICS Inks Partnership Agreement with StableBody Technologies LLC 119 UCLA Further Refines 'NanoVelcro' Device to Capture Single Cancer Cell from Blood 120 Roche to Support Liquid Biopsy in Development of New CTC Detection Method 121 NCI/NIH Grants Phase II SBIR Contract to Epic Sciences for the Development of a Lung Cancer Diagnostic Blood Test 121 Veridex (now Janssen Diagnostics) Collaborates with LabCorp to Market CellSearch® CTC Test in China 121 Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology focused Pipeline 122 NCI/NIH Grant Phase II SBIR Contract to Epic Sciences for Development of Lung Cancer Diagnostic Blood Test 122 New Category I CPT Codes and Payment Rates with Effect from 1st January for Circulating Tumor Cell Testing 123 Cynvenio Biosystems Launches LiquidBiopsy® Lab Service for Molecular Characterization of Circulating Tumor Cells for Identification of Cancer DNA Mutations 123 CELLSEARCH® 'Liquid Biopsy' Approved for Breast Cancer Patients in China 124 Abbott to Adopt Cell Imaging Software for its Automated Vysis ALK FISH Probe Test 124 Fluxion Launches IsoFlux System for Circulating Tumor Cell Analysis 125 Data Continues to Support Innovative Circulating Tumor Cell Program 125 ApoCell’s ApoStream™ CTC Isolation Technology Being Used To Explore Biomarkers as Part of Phase 3 Global Study in Metastatic Breast Cancer 126 Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients 126 Affymetrix Expands QuantiGene® ViewRNA License for In-vitro Diagnostics to become Exclusive Licensee for Chromogenic Applications 126 Revised Coding and Payment Rates Likely for CTC Testing 127 Epic Sciences Enters into Partnerships with Six Pharma Cos. 127 Cynvenio Biosystems Solution for Sequencing Circulating Tumor Cells Isolated from Whole Blood 128 Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced Prostate Cancer 128 Affymetrix Completely Acquires eBioscience Holding Company 128 Fluxion Biosciences Partners with Rubicon Genomics for CTC Analysis 129 BioView Enters into Worldwide Commercial CTC Collaboration with ScreenCell 129 Fluxion Biosciences Collaborates with Stanford University School of Medicine for Developing New Technique to Analyze CTCs 129 TeloVISION LLC Partners with Purdue Research Park to Develop Low Cost Diagnostic Products 129 IVDiagnostics Establishes a New Office in Northwest Indiana 130 COMET-1 Pivotal Trial Initiated by Exelixis for Advanced Prostate Cancer 130 Affymetrix Enters into a Global Distribution Agreement with ScreenCell over CTC Technology 131 Fluxion Biosciences Establishes New Discovery Services Division 131 Silicon Biosystems Establishes a New Laboratory in San Diego to Support Market Expansion in the US 132 OLYMPUS Europa Extends Cooperation with Applied Spectral Imaging 132 Wyss Institute Joins Hands with Children's Hospital Boston to Develop a Microfluidic Device for Culturing Rare CTCs for Diagnosis and Treatment of Cancer 132 Veridex (now Janssen Diagnostics) Joins Hands with Novartis to Promote Circulating Tumor Cells Study in Metastatic Prostate Cancer 133 Clearbridge BioMedics Obtains ISO 13485 Certification for Proprietary ClearCell™ System 133 Convention Biosystems Sign Agreement with NCI on Lung Cancer CTC Development 134 ANGLE Plc Joins Hands with Paterson Institute for Cancer Research 134 Clarient Together with Biocept Launch a New CTC Blood Test to Monitor the HER2 Status in Breast Cancer Patients 135 Transgenomic Collaborates with MD Anderson for Research on Circulating Tumor Cells using ICE COLD-PCR 135 Atossa Genetics Unveils the Latest ArgusCYTE Breast Health Test(SM) for CTC Detection 136 Transgenomic Signs a Worldwide Distribution Agreement with ScreenCell for Circulating Tumor Cell (CTC) Technology 136 Biocept Receives US Patent for its CTC (Circulating Tumor Cell) Platform 137 Biocytics Attains CAP Accreditation 137 Fluxion Biosciences Launches the New Early Access Program for its Proprietary Isoflux Rare Cell Access System 138 Clearbridge and Abnova Collaborate for the Development of an In-Vitro CTC System 138 Silicon Biosystems and Fox Chase Cancer Center Enter into Collaboration for the DEPArray™ Technology Applications 139 IV Diagnostics Gets US $244,479 in Grants under the Qualifying Therapeutic Discovery project Program (QTDP) 139 ApoCell Inks a Contract worth $2.9 Million with SAIC-F for Manufacturing and Marketing ApoStream™ 139 Bioconcept Launches ‘OncoCEE-BR™’, a New CTC (Circulating Tumor Cell) Based Test for Breast Cancer 140 ApoCell Launches into the Market, a Novel Platform to Detect Circulating Cancer Cells 140 Centocor Ortho Biotech Adopts a New Corporate Identity as Janssen Biotech, Part of the Janssen Pharmaceutical Company 141 IntegenX Allies with NuGEN to Advance the Workflow of NuGEN Next-Generation Sequencing (NGS) Sample Preparation 141 Advanced Cell Diagnostics Collaborates with Definiens for the Development of Quantitative Biomarker Analysis Solutions 141 Fluidigm Launches BioMark ™ HD Real-Time PCR System 142 Veridex (now Janssen Diagnostics) and Massachusetts General Hospital Strategically Ally with Each other for State-of-the-Art CTC Technology 142 NCI (National Cancer Institute) Awards Research Grant to Advanced Cell Diagnostics, Inc. (ACD) to Further Enhance its CTCscope™ system to Detect and Analyze CTCs in the Blood 143 Phase II Trial for the Assessment of OGX-427 Treatment in Men with Advanced Prostate Cancer Initiated by OncoGenex Pharmaceuticals 144 IMEC and its Partners in Europe Initiate Project ‘MIRACLE’ for Fast and Cost-effective Cancer Diagnosis 144 AdnaGen Inks two Exclusive contracts with TATAA Molecular Diagnostics 145 Lab21 Launches the CE Marked AdnaGen’s System in the UK and Ireland 145 NCI of the United States Awards a Grant of $200K to Fluxion Biosciences to Develop Rare Cell Isolation Platform 145 AdnaGen and OncoVista Attains a US Patent for CTC Detection and Analysis Technology 146 Sparton Attains Top Position for CTC technology under Medical Innovation for 2009 at the Cleveland Clinic’s Medical Innovations Summit 146 Sysmex Europe Signs Agreement for the Distribution of AdnaGen Products Related to CTC Analysis 146 Affymetrix Takes Over Panomics 147 Advalytix Strategically Allies with M. D. Anderson Cancer Center to Study Single Circulating Tumor Cells 147 Veridex (now Janssen Diagnostics) Acquires Immunicon 148 Immunicon Receives FDA Clearance for CellSearch™ Circulating Tumor Cell Kit to Screen Metastatic Prostate Cancer Patients 148 CTC Technologies - Analysis by Cancer Type 149 Exhibit 29. CTC Technologies by Type – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prostate Cancer, Breast Cancer and Other 149 Exhibit 30. CTC Technologies by Type – Global Market Shares (2010 & 2015) for Prostate Cancer, Breast Cancer and Other 150 Global Market for CTC Technologies in Prostate Cancer 150 Global Market for CTC Technologies in Breast Cancer 150 United States Market for CTC Technologies in Cancer Types 151 Exhibit 31. CTC Technologies by Type – United States Market Estimations and Predictions (2010-2020) in US$ Million for Prostate Cancer, Breast Cancer and Other 151 Exhibit 32. CTC Technologies by Type – United States Market Shares (2010 & 2015) for Prostate Cancer, Breast Cancer and Other 152 United States Market for CTC Technologies in Prostate Cancer 152 United States Market for CTC Technologies in Breast Cancer 152 Analysis by Function 153 Exhibit 33. CTC Technologies by Function – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prognostics, Diagnostics and Therapy Management 153 Exhibit 34. CTC Technologies by Function – Global Market Shares (2010 & 2015) for Prognostics, Diagnostics and Therapy Management 154 Global Market for CTC Technologies in Diagnostics 154 Global Market for CTC Technologies in Prognostics 154 Global Market for CTC Technologies in Therapy Management 154 United States Market for CTC Technologies in Cancer Function 155 Exhibit 35. CTC Technologies by Function – United States Market Estimations and Predictions (2010-2020) in US$ Million for Prognostics, Diagnostics and Therapy Management 155 Exhibit 36. CTC Technologies by Function – United States Market Shares (2010 & 2015) for Prognostics, Diagnostics and Therapy Management 156 United States Market for CTC Technologies in Diagnostics 156 United States Market for CTC Technologies in Prognostics 156 United States Market for CTC Technologies in Therapy Management 156 Circulating Tumor Cells (CTC) Technologies – Market Outlook 157 4. PRODUCT/TECHNOLOGY RESEARCH 159 Circulating Tumor Cells (CTCs) – Key Observations 159 CTC Detection 160 The Hampering Facts 160 CTC Detection – Molecular Targets 160 CTC Enumeration 160 Exhibit 37. Novel Methods for Circulating Tumor Cell Identification and Main Conclusion(s) 161 CTC Enrichment 161 Exhibit 38. CTC Enrichment Methods 162 Source: NIH 163 CTC Capture 164 CTC Isolation 164 Microfluidic Devices 164 CTCs and Cancer Stem Cells (CSCs) 165 Signaling Pathways 165 Surface Markers 165 Cancer Biomarkers 166 Tumor Marker 167 Cells as Biomarkers 168 Circulating Tumor Cells (CTCs) – Cancer Biomarkers 168 Functions of Biomarkers 169 Metronomic Chemotherapy for Cancer Treatment 169 Dispersal of Tumor Cells 170 Biology of Circulating Tumor Cells 171 Potential and Proliferative activity of Circulating Tumor Cells 171 CTCs and Epithelial Marker Genes 171 CTCs and Mesenchymal Transition 172 Stem Cell-like phenotype of CTCs 173 Changed Geno/Phenotype of CTCs when compared to Primary Tumor 173 Epithelial Mesenchymal Transition 173 Presence of CTCs in Epithelial Mesenchymal Transition and Disseminated Disease 174 Mesenchymal and Cancer Stem Cells 174 qPCR Expression Markers 175 Characterization of Protein Expression and Signaling in CTCs 175 Significance of Circulating Tumor Cells 176 Detection of CTCs and its Significance 176 CTC-Receptors 178 Major Causes of Metastasis 178 Cancer 178 Progesterone receptor Positive 179 HER-2 Positive Receptor 179 Triple Negative Type of Tumor 180 Mice models for CTC studies 181 CTC Count Prominence 181 Recent Technique on Cancer Prognosis 182 Immunofluorescent Staining Technique 182 FAST scanning 182 SERS Technology 183 CellSearch® System 183 Biochip Platforms 183 Photoacoustic Spectroscopy 184 Immunomagnetic Separation 184 Immunohistochemistry 185 CISH Technique 186 FISH Technique 186 Nanotechnology 187 Tagged- Amplicon Sequencing Technique 187 CTC Technologies 187 Techniques for Detection and Manipulation 187 Function-Based Methods 187 Nonfunction-Based Techniques 189 In Vivo CTC Manipulation Techniques 190 Challenges to In Vivo Manipulation Devices 191 Advanced CTC Detection Technologies Based on Genomics 192 CTC and Cancer Type 192 Introduction 192 Breast Cancer Therapy using Circulating Tumor Cells 193 CTC found in Early Metastasis 193 CTC Detection Methods 194 CTCs as a Biomarker in Advanced Breast Cancer 195 Detection of CTCs in Prostate & Colorectal Cancers 195 CTCs in Ovarian Cancer 196 Exhibit 39. Cancer Type and Respective Detection Methods and Markers 196 CTC Diagnosis and Prognosis 197 Circulating Tumor Cell based PSA as a Biomarkers in Prostate Cancer Prognosis 197 Exhibit 40. Clinical Studies Evaluating Circulating Tumor Cells as a Prognostic Tool 198 CTCs as Therapy Response Marker 199 CTCs in Custom-Made Medicine 200 Circulating Tumor Cells (CTC) Technologies - Research Briefs 201 Researchers Discover Cancer Cell Mechanism for Metastatic Brain Tumor Development 201 DNA Shed by Tumors have Potential for Non-Invasive Screening, Diagnosis 201 Clinical Waste May be Useful to Monitor Treatment Response in Ovarian Cancer 203 Liquid Biopsy - Enhances Cancer Diagnosis and Treatment 204 Circulating Tumor Cell Enumeration 205 Separation and Isolation of Live Tumor Cells 206 Metastasis Stem Cells Found in Blood of Breast Cancer Patient 206 Human Scabs is an Inspiration for Novel Bandage to Expedite Healing 208 Circulating Breast Tumor Cells Signature Found 208 Third Generation Gadget to Help Capturing Circulating Tumor Cells 209 Finding Circulating Tumor Cells 210 ‘NanoVelcro’ Gadget to Capture Single Cancer Cells from Blood 211 Circulating Epithelial Tumor Cell (CETC) Analysis as a Diagnostic Tool for the Prognosis of Metastatic Relapse and Progression of Cancer 212 Plastin3 is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and is Associated with Colorectal Cancer Prognosis. 212 Segregating Circulating Tumor Cells using Centrifugal Forces 213 High Demands on the Cancer Diagnosis of Colon Cancer 213 Scientists Develop New Technique for the Capturing Cancer Tumor Cells from the Blood 214 Comparison between CTCs, Cancer Stem Cells and Normal Stem Cells 215 Circulating Tumor Cells as the Therapy-Related Biomarkers in Cancer Patients 215 Nanoscale Velcro-like Device Developed by Scientists to Capture and Release the Circulating Tumor Cells in Bloodstream 216 A New Nanostructure Surfaces designed to Target and Kill Circulating Tumor Cells Avoiding Leukocytes Developed by Scientists 216 A Novel CTC Isolation Platform using Selective Size Amplification (Ssa) and a Multi-Obstacle Architecture (Moa) Filter Known as Ssa-Moa Developed 217 Circulating Tumor Cells (CTCs) and Epithelial Mesenchymal Transition in Primary Breast Cancer Patients 217 Chip-Based Nanostructured Sensors Help In Precise Recognition and Categorization of Circulating Tumor Cells (CTCs) in Blood Samples taken from the Patients of Prostate Cancer 218 A New Micro Fluidic Platform using Optically-Induced-Dielectrophoretic (Odep) Force Developed for the High-Purity and Label-Free Isolation of Circulating Tumor Cells (Ctcs) 219 Highly Efficient Assay of Circulating Tumor Cells by Selective Sedimentation with a Density Gradient Medium and Microfiltration from Whole Blood 219 Breakthrough in Personalized Cancer Treatment 220 Dielectrophoresis (DEP) Technique Emerges as a New Technique for the Isolation of Circulating Tumor Cells 221 Link Between Origin of cfDNA and CTCs 221 Demystifying Circulating Tumor Cells 222 Presence of Disseminated Tumor Cells after Neoadjuvant Therapy for Locally Advanced Breast Cancer Indicates Poor Survival 223 DETECT Study initiated for In-Depth Understanding of the Prominence of Circulating Tumor Cells in Metastatic Breast Cancer Patients 223 Hepatocellular Carcinoma and CTCs – Methods used for Detection, Clinical Consequences and Future Prospects 224 CTCs in Metastatic Colorectal Cancer –A Challenge to Researchers 224 CTCs in Non-Metastatic Breast Cancer –an Upcoming Study 225 A Study on Circulating Tumor Cells in Non-Metastatic Breast Cancer 225 CTCs for the Prediction of PFS (Progression-Free Survival) and OS (Overall Survival) in Patients with Relapsed/Recurrent Ovarian Cancer 226 CTCs in Breast Cancer – Challenges of Molecular Characterization and Promise of Customized Treatment 226 University of Texas MD Anderson Cancer Center Develops a Method for Predicting CTCs in the Early Stage Breast Cancer 227 Single Cell Summary of Circulating Tumor Cells: Transcriptional Variety and Range from Breast Cancer Cell Lines 228 Secreted Vesicles Assist the Spread of Cancer in the Body 228 CTCs Very Useful for the Treatment of MBC (Metastatic Breast cancer) Except for HER2 Positive Cases 230 Biomarkers Characterized Using CTCs in Breast Cancer Patients 231 Tumor Cells are Unequal and Demonstrate Large Genetic Diversity: a Stanford Study 231 Classifying CTCs with Prostate-Cancer –Specific Micro fluidic Instrument 233 Estimation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib 233 ApoCell Introduces New Technology for CTC Capture to Identify the Lethal Liver Cancer Cells 234 Clinical Utility and Performance Validation Data Given by On-Q-ity on its Dual capture OnQChip™ 235 ANGLE plc Unveils Novel PARSORTIX GEN2 SEPARATION CASSETTE, a Breakthrough Device for Cell Separation and CTC Capture 235 Lilly Conducts Study on the Flawed c-MET Receptor in Cancer Research Studies 237 Scientists Develop New Blood Tests to indentify Rare Circulating Tumor Cells 237 Epithelial Mesenchymal Transition: A Novel Methodology for CTC Detection 238 Scientists Develop a New Microdevice to Culture Isolated Rare Circulating Tumor Cells 238 Spotting of CTC through Photo Acoustic System for Early Melanoma Detection 239 Scripps Research Institute Discovers a Novel Technique to Diagnose Cancer at an Early Stage 239 Serum Marker and CTC Assessment to Evaluate the Period of progression-free survival (PFS) in Metastatic Breast Cancer 241 A Diagnostic Gene Expression Profile that Shows Presence of CTCs in Patients of Breast Cancer 241 mRNA-Seq of Individual Prostate Cancer CTCs shows Recapitulation of Gene Expression and Pathways seen in Prostate Cancer 242 Growth of Tumor-Spheres from Peripherally Circulating Tumor Cells 242 Circulating Tumor Cells and Metastasis, Clinical Efficacy in Lung Cancer Treatment 243 Changes in Tumor Cells Leads to Metastasis: a Study by the University of Granada 243 Circulating Tumor Cells Analyzed in Lung Cancer by Sensitive Detection Method 244 Impartial, Automatic Identification of a Circulating Tumor Cell Definition that Linked with Survival 244 Locating Circulating Tumor Cells for Cancer Therapy 245 Recognition and Molecular Characterization of CTCs in Breast Cancer 245 Development of Organ-specific Markers for Identifying Circulating Tumor Cells 246 Diagnostic Value of HER2 positive Circulating Tumor Cells in Metastatic Breast Cancer Patients 247 Analyzing Circulating Tumor Cells in Metastatic Breast Cancer using Artificial Neural Network Analysis 247 Use of CTCs of MBC in Patients Receiving First-Line Systemic Treatment 248 CTCs and DTCs of Primary Breast Cancer 248 Duke Cancer Institute Discover the Mechanism of the Spread of Cancer 248 Researchers Develop a New Technique based on Blood Analysis for Predicting the Effect of Drugs on Prostate Cancer 249 Strong Evidence Backs the Prognostic Value of CTCs for the Treatment of Breast Cancer 250 Analysis Conducted on a Huge Scale Reveals that Blood Test could be a “Powerful Predictor” 251 CTCs Hold Clues to an Enhanced Treatment for Breast Cancer Treatment 251 Identifying Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients who Underwent Therapy 252 ‘Nano-Velcro’ Technology Adopted by UCLA Researchers to Develop Capture Circulation Cancer Cells 252 Use of Nano-partIcles Advantageous for CTC Detection 253 Cross Contamination – Free Flow Cytometry Permits Quantification of Intact CTCs 254 Categorization of MBC Patients with Unrecognized Circulating Tumor Cells 255 Latest and Upcoming Biomarkers in Breast Cancer Diagnosis and Forecast 255 Scientist Developed a Molecular Biomarker Analysis Using Circulating Tumor Cells for Cancer Detection 256 Microfluidic Devices – A New technology for the Capture of CTCs 256 CTC Based Assays for Early Detection and Prognosis of Cancer for Effective Advance in Cancer Treatment 257 Advanced CTC Analysis using Molecular Techniques Developed for Personalized Treatment of Cancer Patients 257 Assay Procedure Developed for CTC Detection in Patients Undergoing Surgery for Hepatic Metastases in Colorectal Cancer 257 CellSearch System for CTC Detection in Metastatic Breast Cancer 258 Cancer Management Clinches New Heights 258 CTCs as Genetic Signature for Detecting Lung Cancers 258 Scientists Develop New Method of Detection of CTC Using Reverse-Transcription Polymerase Chain Reaction (RT-PCR) 259 Scientists Develop Fiber-Optic Array Scanning Technology for Rare Cancer Cell Detection 260 Circulating Tumor Cells Associated with Melanoma 260 Microchip Technology to Isolate Rare CTCs 261 New In Vivo Screening Method that Scans Surface Veins for Circulating Tumor Cells 261 CTCs in Preoperative Esophageal Cancer Patients: Quantitative Assay System 262 Presence of Apoptotic and Non Apoptotic Disseminated Tumor Cells Reflect Response to Neoadjuvant Systemic Therapy (NST) in Breast Cancer 263 Significance of Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micro-metastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity 263 5. CORPORATE DIRECTORY 265 6. PATENTS INFORMATION 279 7. CLINICAL TRIALS 363
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
